Back to results
US 2016/0243095 A1Published application
Compositions for the treatment of cns-related conditions
AssigneeAdamas Pharmaceuticals, Inc.
InventorsGregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.
Claims10
A method of treating a patient with a neurological condition, comprising orally administering to a human subject in need thereof:
- (a) 22.5 mg to 30 mg memantine or a pharmaceutically acceptable salt thereof provided in a sustained release dosage form, wherein said sustained release memantine provides a change in mean plasma concentration of memantine as a function of time (dC/dT) that is:
- (1) less than about 50% of the dC/dT provided by the same quantity of an immediate release form of memantine, determined in a time period between 0-Tmax of the immediate release form of memantine;
- and (2) 2.1 ng/ml/hr or less, determined in a time period of 0 to 4 hours;
- wherein dC/dT is measured in a single-dose human PK study;
- and
- (b) a therapeutically effective amount of immediate release donepezil.
3 more elements
Dependencies are inferred from the claim text.